Partnering
Business Development
Partnerships and collaborations are a key part of HiFIBiO’s strategy.
We are open to flexible partnership models - out-licensing, development and research collaborations, academic alliances - to maximize the potential of our novel pipeline candidates and to harness the power of our proprietary Drug Intelligence Science (DIS®) platform.
Our DIS® approach provides a uniquely flexible single cell solution for target, antibody, and biomarker discovery.
Areas of interest
Pipeline
Robust product portfolio focused on immune modulation to treat cancer and autoimmune diseases
- Out-license of select pipeline assets for global development and commercialization
- Collaborations to explore novel combinations with HiFiBiO's pipeline assets
- Collaborations to identify and develop novel therapeutic antibodies
Platform
Proprietary Drug Intelligence Science (DIS®) approach provides a uniquely flexible single cell solution for target, antibody, and biomarker discovery
- Indication selection and biomarker discovery for advanced patient stratification
- Discovery and validation of novel therapeutic targets
- Translational analysis of HiFiBiO's single-cell database
Pipeline
Robust product portfolio focused on immune modulation to treat cancer and autoimmune diseases
- Out-license of select pipeline assets for global development and commercialization
- Collaborations to explore novel combinations with HiFiBiO's pipeline assets
- Collaborations to identify and develop novel therapeutic antibodies
Platform
Proprietary Drug Intelligence Science (DIS®) approach provides a uniquely flexible single cell solution for target, antibody, and biomarker discovery
- Indication selection and biomarker discovery for advanced patient stratification
- Discovery and validation of novel therapeutic targets
- Translational analysis of HiFiBiO's single-cell database
Please contact our Business Development Team.
Select Current and Previous Partners
HiFiBiO Therapeutics announced a clinical trial supply agreement with Novartis
Read More
FibroGen, Inc. and HiFiBiO Therapeutics, announced an extension of their partnership
Read More
HiFiBiO Therapeutics announced a publication in Science in collaboration with the Coronavirus Immunotherapy Consortium (CoVIC)
Read More
FibroGen, Inc. and HiFiBiO Therapeutics, announced a partnership covering three HiFiBiO programs.
Read More
Kite and HiFiBio Therapeutics Partner to Discover Novel Targets and Antibodies Against Acute Myeloid Leukemia
Read More
Research Collaboration to Develop Technology for the Treatment of Cancer
Read More
Research Collaboration to Develop Technology for the Treatment of Cancer
Read More
Read our article in Drug Discovery Today for more information on our open-innovation strategy
Read More